BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 30049502)

  • 1. Real-world Clinical Characteristics, Treatment Patterns, and Exacerbations in US Patients With Asthma Newly Treated With Omalizumab.
    Ke X; Kavati A; Wertz D; Huang Q; Wang L; Willey VJ; Stephenson JJ; Ortiz B; Panettieri RA; Corren J
    Clin Ther; 2018 Jul; 40(7):1140-1158.e4. PubMed ID: 30049502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection.
    Jeffery MM; Shah ND; Karaca-Mandic P; Ross JS; Rank MA
    J Allergy Clin Immunol Pract; 2018; 6(5):1568-1577.e4. PubMed ID: 28958746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Characteristics and Treatment Patterns in Patients with Urticaria Initiating Omalizumab in the United States.
    Ke X; Kavati A; Wertz D; Huang Q; Wang L; Willey VJ; Stephenson JJ; Ortiz B; Paknis B; Bernstein JA; Beck LA
    J Manag Care Spec Pharm; 2018 Jul; 24(7):598-606. PubMed ID: 29952712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.
    Lafeuille MH; Dean J; Zhang J; Duh MS; Gorsh B; Lefebvre P
    Ann Allergy Asthma Immunol; 2012 Jul; 109(1):59-64. PubMed ID: 22727159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma.
    Grimaldi-Bensouda L; Zureik M; Aubier M; Humbert M; Levy J; Benichou J; Molimard M; Abenhaim L;
    Chest; 2013 Feb; 143(2):398-405. PubMed ID: 23505637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between consistent omalizumab treatment and asthma control.
    Lafeuille MH; Gravel J; Zhang J; Gorsh B; Figliomeni M; Lefebvre P
    J Allergy Clin Immunol Pract; 2013 Jan; 1(1):51-7. PubMed ID: 24229822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study.
    Chen HC; Huang CD; Chang E; Kuo HP
    BMC Pulm Med; 2016 Jan; 16():3. PubMed ID: 26747278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).
    Niven RM; Saralaya D; Chaudhuri R; Masoli M; Clifton I; Mansur AH; Hacking V; McLain-Smith S; Menzies-Gow A
    BMJ Open; 2016 Aug; 6(8):e011857. PubMed ID: 27507234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthma.
    Blanchette CM; Culler SD; Ershoff D; Gutierrez B
    Clin Ther; 2009 Nov; 31(11):2574-83. PubMed ID: 20110003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma.
    Pilon D; Kavati A; Ortiz B; Paknis B; Vegesna A; Schiffman B; Zhdanava M; Lefebvre P; Stone B
    Allergy Asthma Proc; 2018 Mar; 39(2):127-135. PubMed ID: 29208079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.
    Chipps BE; Figliomeni M; Spector S
    Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant asthma medication use in patients receiving omalizumab: results from three large insurance claims databases.
    Lafeuille MH; Duh MS; Zhang J; Wertz D; Gu T; Swensen A; Lefebvre P
    J Asthma; 2011 Nov; 48(9):923-30. PubMed ID: 21978232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab.
    Chen H; Eisner MD; Haselkorn T; Trzaskoma B
    Respir Med; 2013 Jan; 107(1):60-7. PubMed ID: 23083840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of combination fluticasone propionate and salmeterol or inhaled corticosteroids on asthma-related outcomes in a Medicare-eligible population.
    Stanford RH; Blanchette CM; Roberts MH; Petersen H; Fuhlbrigge AL
    Am J Geriatr Pharmacother; 2012 Dec; 10(6):343-51. PubMed ID: 23083688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
    Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled corticosteroid use and outcomes in pregnancy.
    Schatz M; Leibman C
    Ann Allergy Asthma Immunol; 2005 Sep; 95(3):234-8. PubMed ID: 16200813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach: The Real-life Effectiveness of Omalizumab Therapy (REALITY) study.
    Singh H; Peters JI; Kaur Y; Maselli DJ; Diaz JD
    Ann Allergy Asthma Immunol; 2019 Nov; 123(5):476-482.e1. PubMed ID: 31382020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 'Real-life' experience in asthmatic children treated with omalizumab up to six-years follow-up.
    Folqué MM; Lozano J; Riggioni C; Piquer M; Álvaro M; Machinena A; Giner MT; Domínguez O; Jiménez-Feijoo RM; Dias da Costa M; Plaza AM
    Allergol Immunopathol (Madr); 2019; 47(4):336-341. PubMed ID: 30509559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study.
    Chung Y; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Carstens D
    J Med Econ; 2023; 26(1):954-962. PubMed ID: 37441729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.